Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from TuHURA Biosciences ( (HURA) ) is now available.
On November 3, 2025, TuHURA Biosciences entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to potentially sell up to $50 million in common stock. The proceeds from this offering are intended for working capital and general corporate purposes, although there is no obligation to sell shares, and the agreement can be suspended or terminated by either party.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. operates in the biotechnology industry, focusing on developing and offering innovative bioscience solutions. The company is involved in the sale of common stock to raise capital for its operations.
Average Trading Volume: 393,717
Technical Sentiment Signal: Strong Sell
Current Market Cap: $129.8M
Find detailed analytics on HURA stock on TipRanks’ Stock Analysis page.